Abstract
The critical plasma anticoagulant protein S (PS) circulates in 2 functionally distinct pools: free (anticoagulant) or bound to complement component 4b-binding protein (C4BP; anti-inflammatory). Acquired free PS deficiency is detected in several viral infections, but its cause is unclear. Here, we used biochemical approaches and human patient plasma samples to identify an interaction between PS and von Willebrand factor (VWF), which causes free PS deficiency and reduced PS anticoagulant activity. We first identified a shear-dependent interaction between PS and VWF by mass spectrometry. Consistently, PS and VWF could be crosslinked together in plasma, and plasma PS and VWF comigrated in gel electrophoresis. The PS/VWF interaction was blocked by and tissue factor pathway inhibitor but not activated protein C, suggesting an interaction with the sex hormone binding globulin region of PS. Microfluidic systems demonstrated that PS stably binds VWF as VWF unfolds under turbulent flow. PS/VWF complexes also localized to platelet thrombi under laminar arterial flow. In thrombin generation–based assays, shearing plasma decreased PS activity, an effect not seen in the absence of VWF. Finally, free PS deficiency in patients with COVID-19 correlated with changes in VWF, but not C4BP, and with thrombin generation. Our data indicate that PS binds to a shear-exposed site on VWF, thus sequestering free PS and decreasing its anticoagulant activity, which would account for the increased thrombin generation potential. Because many viral infections present with free PS deficiency, elevated circulating VWF, and increased vascular shear, we propose that the PS/VWF interaction reported here is a likely contributor to virus-associated thrombotic risk.
| Original language | English |
|---|---|
| Article number | 100030 |
| Journal | Blood Vessels, Thrombosis and Hemostasis |
| Volume | 2 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2025 |
Bibliographical note
Publisher Copyright:© 2024 The American Society of Hematology
Funding
The authors thank Etheresia Pretorius for her advice about the thioflavin T procedure. This study was supported by National Heart, Lung, and Blood Institute grants HL150818 (S.W.W.), HL129193 (J.P.W.), HL145262 (J.A.L.), HL007093 (M.Y.M.), Department of Veterans Affairs Merit I01BX003877 (S.W.W.), and University of Kentucky Center for Clinical and Translational Science pilot grants (J.G.W. and J.P.W.). The University of Kentucky Flow Cytometry & Immune Monitoring core facility is supported in part by the Office of the Vice President for Research, the Markey Cancer Center, and an National Cancer Institute Center Core support grant (P30 CA177558). This study was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1TR001998. Contribution: M.M.S.S. and J.P.W. designed and performed experiments, analyzed data, and wrote the first draft of the manuscript; M.Y.M. H.R.A. M.H. D.W.C. X.F. S.G. D.M.C. K.S.P. M.B. C.P. and X.L. designed and performed experiments and analyzed data; J.P.W. J.A.L. J.G.W. B.A.G. and S.W.W. designed the study and critically revised the manuscript; D.W.C. D.F.D. and Z.Z. critically revised the manuscript; A.C.T. J.Z.P. J.L.S. G.A.S. M.B.-B. and K.S.C. recruited the patients; and all authors reviewed the final version of the manuscript and approved its submission. This study was supported by National Heart, Lung, and Blood Institute grants HL150818 (S.W.W.), HL129193 (J.P.W.), HL145262 (J.A.L.), HL007093 (M.Y.M.), Department of Veterans Affairs Merit I01BX003877 (S.W.W.), and University of Kentucky Center for Clinical and Translational Science pilot grants (J.G.W. and J.P.W.). The University of Kentucky Flow Cytometry & Immune Monitoring core facility is supported in part by the Office of the Vice President for Research , the Markey Cancer Center , and an National Cancer Institute Center Core support grant ( P30 CA177558 ). This study was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health , through grant UL1TR001998 .
| Funders | Funder number |
|---|---|
| University of Kentucky, Center for Clinical and Translational Science | |
| University of Kentucky Markey Comprehensive Cancer Center | |
| Office of the Executive Vice President for Research and Partnerships, Purdue University | |
| National Center for Research Resources | |
| National Center for Advancing Translational Sciences (NCATS) | |
| Department of Veterans Affairs Merit | I01BX003877 |
| National Heart, Lung, and Blood Institute (NHLBI) | HL129193, HL145262, HL007093, HL150818 |
| National Institutes of Health (NIH) | UL1TR001998 |
| National Cancer Institute Center Core | P30 CA177558 |
ASJC Scopus subject areas
- Surgery
- Hematology
- Oncology
- Cardiology and Cardiovascular Medicine
Fingerprint
Dive into the research topics of 'Unfolded von Willebrand factor binds protein S and reduces anticoagulant activity'. Together they form a unique fingerprint.Equipment
-
ChemiDoc Imaging System Bio-Rad
Stowe, A. (Manager), Chen, M. (Operator), Hubbard, W. (Operator), Gipson-Reichardt, C. (Operator), Sullivan, P. (Operator), Roberts, J. (Operator), Trout, A. (Operator), Whiteheart, S. (Operator) & Wood, J. (Operator)
Neuroscience Research Priority AreaEquipment/facility: Equipment